BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ’s COVID-19 Vaccine Globally, and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.

  April 27, 2021

   · 

  5 min read

   · 

  BioSpace Editorial Staff
• 

  Biotech Bay

  With Anti-CD47 Cancer Drugs Trending, Arch Takes in $105 Million for its Antibody

  The race is on in the CD47 field, and Brisbane-based player Arch Oncology just upped the bet with a $105 million Series C raise.

  April 27, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Ceding to Pressure, Biogen Will Offer Early Access to Tofersen in July

  In phase one of the two-part program, access to tofersen will be granted on an individual basis to SOD1-ALS patients with an ALS Functional Rating Scale - Revised (ALSFRS-R) slope decline greater than or equal to 2 points per month.

  April 27, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Aldeyra’s Small Molecule, Reproxalap, Significantly Helps Allergy-Related Eye Symptoms

  Top-line results from the Phase III INVIGORATE trial show Aldeyra Therapeutics’, reproxalap, significantly reduced ocular itching in patients with allergic conjunctivitis.

  April 27, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Lone Star Bio

  Sun’s Out to Play, But So Is Skin Cancer - Here’s What Pharma is Doing About It

  There are several experimental treatments undergoing study for types of melanoma. BioSpace rounds up some of the most recent clinical news in this space.

  April 27, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Two Research Leaders Share How CSL Behring Empowers Teams Across the Globe

  As a devastating pandemic increased scientific collaboration globally, CSL was already ahead of the curve with teams spanning the continents, working together to advance lifesaving treatments and technologies.

  April 27, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  BioMidwest

  Eli Lilly Scraps Psoriasis Drug in Surprising Move

  What makes this particularly surprising is that in July 2020, mirikizumab hit all primary endpoints against placebo and secondary endpoints against Novartis’ Cosentyx in a Phase III OASIS-2 study of plaque psoriasis.

  April 27, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Young Adult COVID-19 Cases Boom as Older Generations Vaccinate

  As vaccinations against COVID-19 continue across the U.S., there appears to be an increase in cases in younger populations.

  April 27, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Policy

  As Drug Prices Climb, Politicians Squabble Over Best Approaches and Timing

  Drug pricing tends to be a somewhat bipartisan issue, although how the Democrats and GOP approach the topic tends to be different.

  April 27, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  FDA

  Trying Again, Enzyvant Resubmits BLA for Pediatric Congenital Athymia Drug

  Enzyvant has resubmitted its Biologics Licensing Application to the U.S. FDA for its tissue-based regenerative pediatric congenital athymia therapy RVT-802.

  April 27, 2021

   · 

  2 min read

   · 

  Brandon May